Europe Ovarian Cancer Diagnostics and Therapeutics Market Size (2024 - 2029)

Europe Ovarian Cancer Diagnostics and Therapeutics Market Analysis

The European ovarian cancer diagnostics and therapeutics market is projected to register a CAGR of 8.6% during the forecast period.

The COVID-19 pandemic affected healthcare systems in Europe and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risk. According to the article by NCBI published in November 2020, surgical mortality in cancer patients who develop peri-operative COVID-19 has been reported to be as high as 25% which led to the postponement and modification of surgical and chemotherapy protocols during the peak of the pandemic. However, with the relaxation of restrictions, post-pandemic circumstances are expected to contribute to the market growth. As per the NCBI article published in January 2021, about 27% of women with ovarian cancer diagnosis faced a considerable change in patient care and support after the pandemic. Such an increase in ovarian cancer patient care during the post-pandemic period is expected to contribute to the growth of the market. The COVID-19 pandemic slowed down the growth rate in early 2020. However, owing to the relaxation of lockdown restrictions and normalization, the studied market is regaining its growth pace.

The major factors that drive the European ovarian cancer diagnostics and therapeutics market are the increasing geriatric women population, the rise in ovarian cancer cases, and the increasing use of combination therapies for the treatment of ovarian cancer. The incidence of ovarian cancer is high among women between the ages of 55 and 64 years. According to the article by OCRA published in May 2021, two-thirds of those diagnosed with ovarian cancer are 55 years or older. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty eating, and urinary symptoms. As per the article by NCBI published in February 2022, ovarian cancer is the fifth most common cancer in Europe for females. Moreover, as per GLOBOCAN estimates for 2020, Europe recorded 74,592 new ovarian cancer cases in 2020. With the rising burden of cancer, there is a rising need for effective treatment.

Additionally, product approvals in Europe are expected to contribute to market growth during the forecast period. For instance, in May 2022, INEX Innovative received CE-IVD certification for its OvaCis Rapid Test for detecting cancer in ovarian cysts. The ovarian cancer product was planned to be launched in the EU markets by the end of the year.

Thus, owing to these factors, the market is expected to witness significant growth during the forecast period. However, the lack of accurate diagnosis of ovarian cancer is expected to restrain the market growth during the forecast period.

Europe Ovarian Cancer Diagnostics and Therapeutics Industry Segmentation

Ovarian cancer is caused by uncontrollable cell growth in the ovarian tissue. It is a growing concern and one of the most common causes of death in women. 

The European ovarian cancer diagnostics and therapeutics market is segmented by cancer type (epithelial ovarian tumors, ovarian germ cell tumors, and other cancer types), modality (diagnosis (biopsy, blood tests, ultrasound, pet, CT scan, and other diagnoses), and therapeutics (chemotherapy, radiation therapy, immunotherapy, hormonal therapy, and other), and geography (Germany, the United Kingdom, France, Spain, Italy, and the Rest of Europe). The report offers the value (in USD million) for the above segments.